Core Insights - Nautilus Biotechnology, Inc. has launched an Early Access Program for its novel proteomics platform, featuring a tau proteoforms assay aimed at accelerating Alzheimer's and neurodegenerative disease research [1][3][4] Group 1: Early Access Program - The Early Access Program allows select researchers to utilize Nautilus' Iterative Mapping method for protein analysis, enhancing the study of diseases like Alzheimer's [1][3] - Participants will receive support from Nautilus for data interpretation and analysis, facilitating rapid adoption and actionable insights [3][4] Group 2: Iterative Mapping Method - Nautilus' Iterative Mapping method enables single-molecule analysis of proteins, achieving comprehensive proteome coverage and detail, which is crucial for understanding post-translational modifications in diseases [2][4] - This method provides a high level of resolution, uncovering biological insights that traditional proteomics methods cannot achieve [2] Group 3: Commercialization and Research Collaboration - The Early Access Program marks a significant step towards commercialization, showcasing the platform's readiness for external use and future capabilities in proteomics [3][4] - Researchers at the Buck Institute for Research on Aging are already utilizing Nautilus' technology to map distinct tau proteoforms, revealing patterns associated with disease progression [5] Group 4: Custom Assays and Future Developments - The program also offers opportunities for exclusive development partnerships to create custom assays tailored to specific research needs [6] - Nautilus plans to host a webinar to discuss the benefits of Iterative Mapping and present updated research data, further promoting its platform [7]